# US 2015/0031892 A1 · Sphingolipid metabolite mimetics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031892 A1
- Document ID: US20150031892A1
- Status: Published application
- Kind: A1
- Application number: 14/511,296
- Filed: 2014-10-10
- Published: 2015-01-29
- Earliest claimed: 2012-10-26
- Assignees: Zhejiang University; Georgia Regents Research Institute, Inc.
- Applicants: Zhejiang University; Georgia Regents Research Institute, Inc.
- Inventors: Feiyan Liu; Kebin Liu; Zhizhen Huang; Ping Wu
- Web page: https://patentgrep.com/patent/US20150031892A1

## CPC

- C07C 237/22: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K)
- C07C 237/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 311/19: to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07D 209/18: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 307/85: attached in position 2
- C07D 333/34: Sulfur atoms
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07C 2601/16: the ring being unsaturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Sphingolipid metabolite mimetics and methods of synthesizing them are provided. The sphingolipid metabolite mimetics are shown to be effective at inducing apoptosis in various types of tumor cells. Further, the sphingolipid metabolite mimetics are shown to be effective at sensitizing multiple types of tumor cells to TRAIL-induced apoptosis. Formulations containing one or more sphingolipid metabolite mimetics and, optionally, one or more cell death receptor agonists are provided. Methods of treating cancer in a subject in need thereof are provided using one or more sphingolipid metabolite mimetics.

## Claims

### Claim 1

(canceled)

### Claim 2

A compound having a structure according to Formula I or Formula II
or a derivative thereof, wherein
Y is hydrogen, methyl, alkyl, or substituted alkyl;
R1 and R3 are alkyl or substituted alkyl; and
R2 and R4 are alkyl, substituted alkyl, aryl, or substituted aryl.

### Claim 3 (depends on 2)

The compound of claim 2 having a structure according to Formula I, wherein
R1 is a C10-C20 linear alkyl, and
R2 is selected from the group consisting of phenyl, 2-furanyl, 2-thiophenyl, 1,3-pentadienyl, 2-phenylethenyl, isoquinoline, indole, methyl indole, benzofuranyl, naphthalene, hydroxynaphthalene, and cyclohex-4-ene-1,2,3-triol.

### Claim 4 (depends on 2)

The compound of claim 2 having a structure according to Formula II, wherein
Y is methyl,
R3 is a C10-C20 linear alkyl, and
R4 is selected from the group consisting of phenyl, 2-furanyl, 2-thiophenyl, 1,3-pentadienyl, 2-phenylethenyl, isoquinoline, indole, methyl indole, benzofuranyl, naphthalene, hydroxynaphthalene, and cyclohex-4-ene-1,2,3-triol.

### Claim 5 (depends on 2)

The compound of claim 2 selected from the group consisting of (S)-2-Amino-3-hydroxy-N-dodecylpropanamide, (S)-2-Amino-3-hydroxy-N-dodecylpropanamide, (2S,3R)-2-Amino-3-hydroxy-N-octadecylbutanamide, (2E,4E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-2,4-hexadienoic acid amide, (2E,4E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-2,4-hexadienoic acid amide, (2E,4E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-2,4-hexadienoic acid amide, (2E,4E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-2,4-hexadienoic acid amide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-Furan-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-Furan-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-benzamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-benzamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-benzamide, N-((2S,3R)-3-Hydroxy-1-oxo-1-(benzamino)butan-2-yl)-tetradecyl acid amide, (E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-3-phenyl acrylic acid amide, (E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-3-phenyl acrylic acid amide, (E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-3-phenyl acrylic acid amide, (E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-3-phenyl acrylic acid amide, (E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-3-phenyl acrylic acid amide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-indole-3-acetic acid amide, N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-isoquinoline-1-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-isoquinoline-1-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-isoquinoline-1-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-2-thiophene carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-2-thiophene carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-2-thiophene carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-benzofuran-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-benzofuran-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-benzofuran-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octylamino)butan-2-yl)-benzamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octylamino)butan-2-yl)-benzamide, (2E,4E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(octylamino)butan-2-yl)-2,4-hexadienoic acid amide, (2E,4E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(octylamino)butan-2-yl)-2,4-hexadienoic acid amide, (2E,4E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(octylamino)butan-2-yl)-2,4-hexadienoic acid amide, (2E,4E)-N-((2S,3R)-3-hydroxy-1-oxo-1-(octylamino)butan-2-yl)-2,4-hexadienoic acid amide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octylamino)butan-2-yl)-benzofuran-2-carboxamide, (2S,3R)-2-Amino-3-hydroxy-N-tetradecylbutanamide, (2S,3R)-2-Amino-3-hydroxy-N-tetradecylbutanamide, (2S,3R)-2-Amino-3-hydroxy-N-tetradecylbutanamide, (2S,3R)-2-Amino-3-hydroxy-N-tetradecylbutanamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-(N-methyl)indole-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-(N-methyl)indole-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-(N-methyl), N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-6-hydroxylnaphthoic-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-6-hydroxylnaphthoic-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-6-hydroxylnaphthoic-2-carboxamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-4-methylbenzsulfonamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-4-methylbenzsulfonamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-4-methylbenzsulfonamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-2-thiophene sulfonamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(dodecylamino)butan-2-yl)-2-thiophene sulfonamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(octadecylamino)butan-2-yl)-2-thiophene sulfonamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-2-naphthylsulfonamide, N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)-2-naphthylsulfonamide, and (3S,4R,5S)-3,4,5-trihydroxy-N-((2S,3R)-3-hydroxy-1-oxo-1-(tetradecylamino)butan-2-yl)cyclohex-1-enecarboxamide.

### Claim 6 (depends on 2)

A method of synthesizing a compound of claim 2 comprising combining, adding into, or mixing one or more organic acids with a compound having the following structure:
or a derivative thereof, wherein
X is hydrogen, methyl, alkyl, or substituted alkyl;
and R1 is alkyl or substituted alkyl.

### Claim 7 (depends on 2)

A method of making a compound of claim 2 comprising:
a) combining, adding into, or mixing one or more primary amines with one or more compounds having the following formula:
to form an intermediate wherein
X is hydrogen, methyl, alkyl, or substituted alkyl; and
Z is an amine-protecting group;
b) removing the amine-protecting group Z; followed by
c) combining, adding into, or mixing one or more organic acids with the intermediate.

### Claim 8 (depends on 2)

A method of synthesizing a compound of claim 2 comprising:
a) attaching one or more amine-protecting groups to an amino acid to form a protected amino acid;
b) combining, adding into, or mixing one or more primary amines with the protected amino acid to form an intermediate;
c) removing the amine-protecting group; followed by
c) combining, adding into, or mixing one or more organic acids with the intermediate to form the compound.

### Claim 9 (depends on 2)

A method of inducing apoptosis in a target cell comprising contacting the target cell with one or more compounds of claim 2.

### Claim 10 (depends on 2)

A method of treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of one or more compounds of claim 2.

### Claim 11 (depends on 2)

A pharmaceutical formulation comprising one or more compounds of claim 2.

### Claim 12 (depends on 11)

The formulation of claim 11 further comprising one or more death receptor agonists.

### Claim 13 (depends on 12)

The formulation of claim 12 wherein the death receptor agonist is TRAIL.

### Claim 14 (depends on 11)

A method of treating cancer in a patient in need thereof comprising administering one or more formulations of claim 11.
